Candel Therapeutics, Inc. (CADL)
Automate Your Wheel Strategy on CADL
With Tiblio's Option Bot, you can configure your own wheel strategy including CADL - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol CADL
- Rev/Share 0.0
- Book/Share 1.4792
- PB 4.1576
- Debt/Equity 0.134
- CurrentRatio 4.6414
- ROIC -0.3926
- MktCap 327943215.0
- FreeCF/Share -0.5391
- PFCF -12.051
- PE -7.8446
- Debt/Assets 0.1044
- DivYield 0
- ROE -1.3674
- Rating C+
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 4
- P/B Score 2
- D/E Score 3
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Resumed | CADL | H.C. Wainwright | -- | Buy | -- | $23 | June 30, 2025 |
| Initiation | CADL | Citigroup | -- | Buy | -- | $25 | Feb. 20, 2025 |
| Initiation | CADL | Canaccord Genuity | -- | Buy | -- | $20 | Feb. 19, 2025 |
| Initiation | CADL | BofA Securities | -- | Buy | -- | $15 | Feb. 7, 2025 |
News
Candel Therapeutics expands Russell Index presence following 2025 reconstitution
Published: July 09, 2025 by: Proactive Investors
Sentiment: Positive
Candel Therapeutics Inc (NASDAQ:CADL) has announced its inclusion in several value-oriented Russell indexes as part of the 2025 Russell US Indexes annual reconstitution. The changes became effective with the opening of the US markets on June 30.
Read More
Candel Therapeutics (CADL) Upgraded to Strong Buy: Here's What You Should Know
Published: June 25, 2025 by: Zacks Investment Research
Sentiment: Positive
Candel Therapeutics (CADL) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Read More
Candel Therapeutics announces $15M direct offering to support CAN-2409 launch preparations
Published: June 24, 2025 by: Proactive Investors
Sentiment: Positive
Candel Therapeutics Inc (NASDAQ:CADL) has announced a $15 million registered direct offering of common stock, the proceeds of which will support launch readiness, medical affairs, and pre-commercialization activities, as well as preparation for a Biologics License Application (BLA) submission for CAN-2409 in prostate cancer, expected in the fourth quarter of 2026. “We are pleased to strengthen our financial position with the resources intended to support pre-commercialization and launch readiness activities for CAN-2409 in prostate cancer, pending regulatory approval, as well as other key corporate purposes,” Candel CEO Dr Paul Peter Tak said.
Read More
Candel Therapeutics Announces $15 million Registered Direct Offering of Common Stock
Published: June 24, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEEDHAM, Mass., June 24, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, has agreed to sell approximately 3.2 million shares of its common stock (Common Stock) to a select group of accredited investors in a registered direct offering (the Offering), at a price per share of $4.67. The Offering is expected to close on June 25, 2025, subject to the satisfaction of customary closing conditions. Gross proceeds from the Offering are expected to be approximately $15.0 million, before deducting offering-related …
Read More
Candel Therapeutics names Charles Schoch as CFO after interim tenure
Published: June 23, 2025 by: Proactive Investors
Sentiment: Neutral
Candel Therapeutics Inc (NASDAQ:CADL) announced that it has appointed Charles Schoch as its chief financial officer. Schoch had served as interim CFO since January 2024 and is being elevated to the permanent position following a key period of operational and financial execution, the company said on Monday.
Read More
Candel Therapeutics Appoints Charles Schoch as Chief Financial Officer
Published: June 23, 2025 by: GlobeNewsWire
Sentiment: Neutral
Interim CFO elevated to permanent role after demonstrating exceptional financial leadership, guiding the company through major operational and financial milestones Interim CFO elevated to permanent role after demonstrating exceptional financial leadership, guiding the company through major operational and financial milestones
Read More
Candel Therapeutics adds biotech veteran Maha Radhakrishnan to Board
Published: June 06, 2025 by: Proactive Investors
Sentiment: Positive
Candel Therapeutics Inc (NASDAQ:CADL) has appointed biotechnology industry veteran Maha Radhakrishnan, M.D., to its board of directors.
Read More
Candel Therapeutics Appoints Maha Radhakrishnan, M.D., to its Board of Directors
Published: June 06, 2025 by: GlobeNewsWire
Sentiment: Neutral
Appointment of seasoned strategic industry executive strengthens the Board of Directors as Candel advances toward Biologics License Application submission and commercial development Appointment of seasoned strategic industry executive strengthens the Board of Directors as Candel advances toward Biologics License Application submission and commercial development
Read More
Does Candel Therapeutics (CADL) Have the Potential to Rally 285.32% as Wall Street Analysts Expect?
Published: June 02, 2025 by: Zacks Investment Research
Sentiment: Positive
The average of price targets set by Wall Street analysts indicates a potential upside of 285.3% in Candel Therapeutics (CADL). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Read More
CADL Up as FDA Grants RMAT Status to CAN-2409 in Prostate Cancer
Published: May 29, 2025 by: Zacks Investment Research
Sentiment: Positive
Candel stock rises as FDA grants RMAT tag to CAN-2409 after phase III success in prostate cancer. BLA submission is planned at the end of 2026.
Read More
Candel Therapeutics get FDA's RMAT designation for prostate cancer therapy
Published: May 28, 2025 by: Proactive Investors
Sentiment: Positive
Candel Therapeutics Inc (NASDAQ:CADL) said on Wednesday the US Food and Drug Administration has granted Regenerative Medicine Advanced Therapy (RMAT) designation to its lead immunotherapy candidate, CAN-2409, for the treatment of newly diagnosed localized prostate cancer in patients with intermediate- to high-risk disease. The RMAT designation is intended to expedite the development and review of regenerative therapies for serious conditions where preliminary evidence suggests the drug may address unmet medical needs.
Read More
Candel Therapeutics to present Phase 3 prostate cancer trial data at ASCO 2025
Published: May 23, 2025 by: Proactive Investors
Sentiment: Positive
Candel Therapeutics Inc (NASDAQ:CADL) announced that it will present results from its positive Phase 3 trial of CAN-2409 in patients with intermediate-to-high-risk localized prostate cancer at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting on June 3 in Chicago. “We are honored that our pivotal phase 3 CAN-2409 data will be presented at the ASCO Annual Meeting, reinforcing the strength of our previously announced results,” Candel CEO Dr Paul Peter Tak said in a statement.
Read More
Candel Therapeutics Presents Positive Phase 3 CAN-2409 Results in Localized Prostate Cancer at ASCO 2025
Published: May 22, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEEDHAM, Mass., May 22, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today announced that results from the Company's positive phase 3 clinical trial of aglatimagene besadenovec (CAN-2409) in patients with intermediate-to-high-risk localized prostate cancer will be presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting taking place in Chicago, IL, from May 30 to June 3, 2025.
Read More
Best Momentum Stocks to Buy for May 19th
Published: May 19, 2025 by: Zacks Investment Research
Sentiment: Positive
CADL, HMN and MAG made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on May 19, 2025.
Read More
New Strong Buy Stocks for May 19th
Published: May 19, 2025 by: Zacks Investment Research
Sentiment: Positive
SUBCY, MAG, KARO, CADL and BPOP have been added to the Zacks Rank #1 (Strong Buy) List on May 19, 2025.
Read More
Wall Street Analysts Predict a 310.96% Upside in Candel Therapeutics (CADL): Here's What You Should Know
Published: May 16, 2025 by: Zacks Investment Research
Sentiment: Positive
The mean of analysts' price targets for Candel Therapeutics (CADL) points to a 311% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Read More
Candel Therapeutics to Present at Upcoming Investor Conferences
Published: May 06, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEEDHAM, Mass., May 06, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, announced today that management will present and participate in one-on-one meetings with investors at upcoming investor conferences.
Read More
Candel Therapeutics reveals new data showing better outcomes for glioma patients using CAN-2409
Published: April 01, 2025 by: Proactive Investors
Sentiment: Positive
Candel Therapeutics Inc (NASDAQ:CADL) shared promising results from a Phase 1b clinical trial testing its experimental cancer therapy, CAN-2409, in patients with newly diagnosed high-grade glioma—a particularly aggressive form of brain cancer. The study, published in Neuro-Oncology, found that CAN-2409, when combined with the immunotherapy drug nivolumab and standard treatments like surgery, radiation, and chemotherapy, was well tolerated and showed signs of boosting the immune system's response to tumors.
Read More
Bears are Losing Control Over Candel Therapeutics (CADL), Here's Why It's a 'Buy' Now
Published: March 25, 2025 by: Zacks Investment Research
Sentiment: Negative
Candel Therapeutics (CADL) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.
Read More
Candel Therapeutics partners with IDEA Pharma on commercialization of lead asset CAN-2409
Published: March 20, 2025 by: Proactive Investors
Sentiment: Positive
Candel Therapeutics Inc (NASDAQ:CADL) announced that it has partnered with IDEA Pharma to advance the commercialization of its lead immunotherapy candidate CAN-2409. The collaboration follows positive Phase 3 data showing CAN-2409 significantly improved disease-free survival in patients with intermediate-to-high-risk localized prostate cancer.
Read More
Candel Therapeutics and IDEA Pharma Announce Strategic Partnership to Advance Path-to-Market Commercialization Efforts for CAN-2409
Published: March 20, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEEDHAM, Mass., March 20, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, together with IDEA Pharma, a Division of SAI MedPartners (IDEA), a pioneering biopharmaceutical strategy consultancy, today announced a strategic commercial partnership.
Read More
Candel Therapeutics appoints cancer immunology expert to research advisory board
Published: March 18, 2025 by: Proactive Investors
Sentiment: Positive
Candel Therapeutics Inc (NASDAQ:CADL) said on Tuesday it has appointed Dr Elizabeth Jaffee to its research advisory board. Jaffee, an internationally recognized expert in cancer immunology and pancreatic cancer, currently serves as the Dana and Albert "Cubby" Broccoli Professor of Oncology and Deputy Director of the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
Read More
Candel Therapeutics CEO discusses promising Phase 2 pancreatic cancer trial results - ICYMI
Published: February 28, 2025 by: Proactive Investors
Sentiment: Positive
Candel Therapeutics Inc (NASDAQ:CADL) CEO Dr Paul Peter Tak talked with Proactive about the encouraging results from the phase 2 trial of its investigational medicine CAN-2409 for borderline resectable pancreatic cancer. Dr Tak shared that the median overall survival in the active treatment group reached 31.4 months, compared to just 12.5 months in the control group, showing a clear separation of survival curves.
Read More
Candel Therapeutics: I Say Stay The Course Despite The Market's Rebuke Of Positive Pancreatic Data
Published: February 25, 2025 by: Seeking Alpha
Sentiment: Positive
Candel Therapeutics' recent phase 2 results in pancreatic cancer showed promising median survival but led to a 20% stock drop due to market skepticism. Despite the drop, I maintain a "Buy" sentiment, emphasizing the significant potential in prostate cancer and the unjustified negative reaction to positive news. CADL's financial health improved with a $92 million share offering, extending their runway to over three years, supporting their ongoing projects.
Read More
Candel Therapeutics Announces Positive Final Survival Data from Randomized Controlled Phase 2 Clinical Trial of CAN-2409 in Non-Metastatic Pancreatic Cancer
Published: February 25, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEEDHAM, Mass., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today announced final overall survival data from the completed randomized controlled phase 2 clinical trial of CAN-2409 plus valacyclovir (prodrug), together with standard of care (SoC) chemoradiation, followed by resection, in patients with borderline resectable PDAC.
Read More
About Candel Therapeutics, Inc. (CADL)
- IPO Date 2021-07-27
- Website https://www.candeltx.com
- Industry Biotechnology
- CEO Paul-Peter Tak FOCIS,
- Employees 38